General Information of Drug (ID: DMUPMCZ)

Drug Name
Dodecane-Trimethylamine Drug Info
Synonyms
DODECANE-TRIMETHYLAMINE; n-Dodecyltrimethylammonium; Dotac compound; Dodecyltrimethylammonium; N,N,N-trimethyldodecan-1-aminium; UNII-GT3793XV5S; 10182-91-9; DODECYLTRIMETHYLAMMONIUM ION; N,N,N-Trimethyl-1-dodecanaminium; dodecyl(trimethyl)azanium; GT3793XV5S; CHEBI:41378; 1-Dodecanaminium, N,N,N-trimethyl-; CHEMBL109873; Lauryltrimethylaminium; dodecyl-trimethyl-azanium; AC1L1QDV; dodecyl(trimethyl)ammonium; AC1Q28RJ; SCHEMBL93498; 112-00-5 (chloride); DTXSID4045008; CHEMBL1180004; 1119-94-4 (bromide); CTK4A0283
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
8153
ChEBI ID
CHEBI:41378
CAS Number
CAS 10182-91-9
TTD Drug ID
DMUPMCZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
JAB-3312 DMNMV0D Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
TNO155 DMZ60X4 Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
JAB-3068 DMSGEU6 Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
BBP-398 DM572ZL Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
SAR442720 DMTAOPC Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
RLY-1971 DMUT4YZ Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
PF-07284892 DMQ6F8X Aggressive cancer 2A00-2F9Z Phase 1 [7]
A380 DMXOZDP Aggressive cancer 2A00-2F9Z Phase 1 [8]
RG6433 DMZM06U Aggressive cancer 2A00-2F9Z Phase 1 [9]
NSC-87877 DMEYKXL Discovery agent N.A. Patented [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Protein-tyrosine phosphatase SHP-2 (PTPN11) TT7WUAV PTN11_HUMAN Inhibitor [1]

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 Clinical pipeline report, company report or official report of AbbVie.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT04528836) First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
5 Clinical pipeline report, company report or official report of Revolution Medicines.
6 Clinical pipeline report, company report or official report of Relay Therapeutics.
7 SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy. Cancer Discov. 2023 Aug 4;13(8):1789-1801.
8 Clinical pipeline report, company report or official report of Klus Pharma
9 Clinical pipeline report, company report or official report of Roche
10 Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J Med Chem. 2008 Aug 28;51(16):4948-56.